PA-LINESIGHT
18.10.2021 16:02:05 CEST | Business Wire | Press release
IPS-Integrated Project Services, LLC , headquartered in Blue Bell, Pennsylvania and a subsidiary of Alleghany Capital Corporation , today announced that it has acquired Linesight, a multinational consulting firm headquartered in Dublin, Ireland. IPS is a large EPCMV (Engineering, Procurement, Construction Management and Validation) company with over 1,700 staff across 22 offices worldwide. Linesight is a fast-growing professional consultancy services organization providing project controls to data center providers, life sciences companies, commercial real estate, healthcare, hospitality, retail and residential sectors. Linesight has over 900 staff across 24 offices globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005645/en/
The acquisition is being approached as a future integrated partnership where IPS will leverage Linesight’s experience and expertise in particular in the data center sector and Linesight in turn will leverage IPS’s expertise in the Life Sciences sector. Both organizations will expand their geographic reach, build on their bench strength and extend their service propositions for their target clients globally. Linesight will continue to serve its clients as it always has, but now has the support of a much larger organization behind it.
Dave Goswami, CEO, IPS stated “This is a transformational transaction for both IPS and Linesight and we are excited to embark on a new growth journey together, supported by Alleghany Capital. By leveraging both companies’ strong track records and combining our skills and management horsepower, we expect to make a meaningful positive difference in the industries we serve. Led by Paul Boylan and a strong leadership team, Linesight is a highly sought after company providing consulting services, including cost and project management, project controls, risk, scheduling and procurement services focused on the data center, life sciences, and other industry sectors.
This fits well with IPS’ complementary services which include engineering, construction management and compliance services. We are thrilled at the prospect of working with the Linesight team to provide a more comprehensive and superior suite of services to our respective clients.”
Paul Boylan, CEO, Linesight added, “This is a pivotal point in Linesight’s long and successful business history and will enable us to deliver on our ambitious strategic plans, expand into new geographies to better service our client needs and extend our portfolio offering in our existing and new target markets. Linesight’s skilled teams will continue to provide the same high-quality levels of service to our clients globally and we see enhanced career opportunities for our people in all our regions. I am energized at the potential of this new business partnership and believe that it positions us well to deliver on our ambitious growth aspirations as we look towards 2022 and beyond.”
About IPS-Integrated Project Services
IPS is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill and passion, IPS provides consulting, architecture, engineering, construction management, and compliance services that allow clients to create and manufacture life-impacting products around the world. Headquartered in Blue Bell, Pennsylvania in the United States, IPS is one of the fastest-growing companies servicing the life sciences industry with over 1,700 professionals in the United States, Canada, Brazil, the United Kingdom, Ireland, Switzerland, Singapore, China, and India. For more information about IPS, please visit www.ipsdb.com
.
About Linesight
Linesight is a multinational consultancy firm with over 45 years' experience, providing cost, schedule, risk, program and project management services to a multitude of sectors including Data Centers, Life Sciences, Commercial, High-Tech Industrial, Residential, Hospitality, Healthcare and Retail. Linesight’s specialist project teams, each with specific skills and experience, provide better predictability of project outcomes, faster project delivery, greater cost efficiency and maximum value for money for its clients. For further information, please visit http://www.linesight.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005645/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom